Midlife baseline prostate‐specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality
The study findings are that PSAV or PSADT were not superior to midlife baseline in assessing the likelihood of developing lethal PCa. This suggests that these variables may not have practical use in enhancing PSA screening strategies in a clinical setting.
Authors
- Giuseppe Ottone Cirulli
- Morrison Chase
- Akshay Sood
- Alberto Briganti (ORCID: https://orcid.org/0000-0002-2178-0494)
- Giovanni Lughezzani
- Nicolò Maria Buffi (ORCID: https://orcid.org/0000-0003-2436-9091)
- Matthew Davis (ORCID: https://orcid.org/0000-0001-9976-3638)
- Marco Finati (ORCID: https://orcid.org/0000-0002-7425-1166)
- Andrea Salonia (ORCID: https://orcid.org/0000-0002-0595-7165)
- Firas Abdollah (ORCID: https://orcid.org/0000-0003-1298-8231)
- Francesco Montorsi (ORCID: https://orcid.org/0000-0002-7267-4181)
- Sohrab Arora (ORCID: https://orcid.org/0000-0001-9903-9316)
- Giuseppe Chiarelli
- Shane Tinsley (ORCID: https://orcid.org/0009-0000-7711-3116)
- Alex Stephens (ORCID: https://orcid.org/0009-0003-5294-2497)
- Giuseppe Carrieri
- Craig A. Rogers
Institutions
- University of Foggia (IT)
- Humanitas University (IT)
- Henry Ford Health System (US)
- Vita-Salute San Raffaele University (IT)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- The Ohio State University Wexner Medical Center (US)
- IRCCS Ospedale San Raffaele (IT)
- IRCCS Humanitas Research Hospital (IT)
Publication Details
- Journal
- Cancer
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1002/cncr.35563
- Citations
- 1
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42